DUBLIN--(BUSINESS WIRE)--The "Global Anti-Viral drugs Market Outlook - Market size, Segmentation, Market Share and Competitive Landscape (2016 - 2021)" report has been added to Research and Markets' offering.
Anti-Viral drugs are the drugs used to treat viral infections which can range from infections like flu to AIDS (Acquired Immuno Deficiency Syndrome). Just like common cold which is also caused by virus, most viral diseases are extremely difficult to cure and what the anti-viral drugs mostly do is slow down the reproduction of virus which in some cases enables immune system to eliminate the virus (as in case of flu) while slowing down the disease progression in other cases (as in case of AIDS).
The need of anti-viral drugs for patient's lifetime in case of diseases like HIV/AIDS along with well-established supply chain that facilitates easy procurement are driving the growth of this market. While the increasing use of generics along with lack of incentivization and lack of curative anti-viral drugs for indications like HIV/AIDS are hindering the growth of this market.
This market has been segmented on the basis of target disease into HIV/AIDS, Hepatitis, Herpes and Influenza. The market has also been segmented by type of anti-viral into IPR Protected and Generic.
Lack of broad spectrum anti-viral drugs is currently the huge unmet need in this market and presents a great opportunity to companies. While the negative impact of viral vaccines on the growth of anti-viral drugs market and increasing focus on prevention rather than cure of viral diseases are currently the challenges faced by this market.
- Johnson & Johnson
- Merck & Co
Key Topics Covered:
2. Executive Summary
3. Market Overview
4. Key Challenges
5. Competitive Landscape
For more information about this report visit https://www.researchandmarkets.com/research/6xkz3j/global_antiviral